Q1 2024 Earnings Estimate for Kodiak Sciences Inc. Issued By Zacks Research (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities researchers at Zacks Research dropped their Q1 2024 earnings estimates for shares of Kodiak Sciences in a note issued to investors on Thursday, November 2nd. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($1.25) for the quarter, down from their previous forecast of ($1.23). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q2 2024 earnings at ($1.22) EPS, Q3 2024 earnings at ($1.20) EPS, Q4 2024 earnings at ($1.15) EPS, FY2024 earnings at ($4.82) EPS, Q1 2025 earnings at ($0.96) EPS and Q2 2025 earnings at ($0.89) EPS.

Several other brokerages have also issued reports on KOD. Chardan Capital lowered Kodiak Sciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 25th. JPMorgan Chase & Co. lowered shares of Kodiak Sciences from a “neutral” rating to an “underweight” rating in a report on Monday, July 24th. Jefferies Financial Group lowered shares of Kodiak Sciences from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. UBS Group cut Kodiak Sciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $4.00 in a report on Thursday, July 27th. Finally, Capital One Financial lowered Kodiak Sciences from an “overweight” rating to an “equal weight” rating and set a $7.00 price target on the stock. in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, Kodiak Sciences presently has a consensus rating of “Hold” and a consensus target price of $7.33.

Kodiak Sciences Trading Up 11.8 %

NASDAQ:KOD opened at $2.36 on Monday. Kodiak Sciences has a 1 year low of $1.37 and a 1 year high of $9.80. The stock has a 50-day moving average price of $1.90 and a two-hundred day moving average price of $4.28. The stock has a market cap of $123.79 million, a price-to-earnings ratio of -0.41 and a beta of 1.79.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Monday, August 14th. The company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.30).

Institutional Trading of Kodiak Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of KOD. Wellington Shields Capital Management LLC raised its stake in shares of Kodiak Sciences by 5.5% during the 4th quarter. Wellington Shields Capital Management LLC now owns 57,220 shares of the company’s stock worth $410,000 after purchasing an additional 3,000 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Kodiak Sciences by 6.0% during the fourth quarter. Alliancebernstein L.P. now owns 56,700 shares of the company’s stock worth $406,000 after buying an additional 3,200 shares during the last quarter. Jane Street Group LLC raised its position in Kodiak Sciences by 16.8% during the first quarter. Jane Street Group LLC now owns 22,540 shares of the company’s stock worth $140,000 after acquiring an additional 3,236 shares in the last quarter. Royal Bank of Canada lifted its stake in Kodiak Sciences by 89.0% in the third quarter. Royal Bank of Canada now owns 7,592 shares of the company’s stock valued at $59,000 after acquiring an additional 3,575 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its position in shares of Kodiak Sciences by 64.4% in the 3rd quarter. Ensign Peak Advisors Inc now owns 9,570 shares of the company’s stock valued at $74,000 after acquiring an additional 3,750 shares during the period. Institutional investors and hedge funds own 80.99% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.